
==== Front
Public Health Pract (Oxf)
Public Health Pract (Oxf)
Public Health in Practice
2666-5352
Elsevier

S2666-5352(24)00076-4
10.1016/j.puhip.2024.100539
100539
Original Research
First-trimester medication abortion via telemedicine: A retrospective cohort study
Cely-Andrade Leonardo jlcelya@unal.edu.co
a⁎
Enríquez-Santander Luis Carlos a
Cárdenas-Garzón Karen a
Saavedra-Avendaño Biani b
Ortiz Avendaño Guillermo Antonio c
a Profamilia, Bogotá, Colombia
b Ipas Latin America and the Caribbean, Mexico City, Mexico
c Ipas Latin America and the Caribbean, North Carolina, United States
⁎ Corresponding author. Calle 104 # 14-86, Bogotá, Colombia. jlcelya@unal.edu.co
23 8 2024
12 2024
23 8 2024
8 1005393 10 2023
16 7 2024
5 8 2024
© 2024 Profamilia
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Background

Following the decriminalization of abortion in Colombia and amidst a global health crisis due to COVID-19, Profamilia implemented a telemedicine-assisted first-trimester Medication Abortion (MAB) program. This is an opportunity to reduce inequalities in access and to promote empowerment and sexual and reproductive rights. This study aims to describe socio-demographic and clinical characteristics of users and to assess its effectiveness and safety.

Study design

A retrospective cohort study.

Methods

The study analyzed data from users who received Profamilia's telemedicine abortion services between August 2021 and August 2022 (n = 3073). A descriptive analysis of their sociodemographic and clinical characteristics was performed, grouping, and comparing them according to follow-up status and abortion outcome. Effectiveness was assessed by the percentage of complete abortions without surgical intervention, and safety by the incidence of complications, potential adverse events, and potentially dangerous signs.

Results

Most of the users were less than 8 weeks gestation at the start of treatment (88.3 %), from low socioeconomic strata (84.8 %), affiliated to the subsidized healthcare system (87.6 %), with educational levels up to secondary school (81.6 %), between 18 and 35 years (87.4 %), from urban areas (97.8 %) and singles (90,8 %). 94.9 % of users had a complete abortion using medication, and 0.3 % of cases reported complications.

Conclusions

First-trimester MAB through telemedicine in the Latin American context is an effective and safe choice. Telehealth is an important strategy to expand access to safe abortion care, especially for those with limited financial means or educational backgrounds. Rural and marginalized populations need more attention to improve access.

Keywords

Cohort study
Medication abortion
Telemedicine
Effectiveness
Safety
Satisfaction
==== Body
pmcResearch in context

Evidence before this study: Prior to the analysis conducted in this study, we performed a systematic literature review on telemedicine medication abortion up to the twelfth week of pregnancy. The search was conducted in January 2023 on the PubMed, Embase, Cochrane, SciELO, LILACS, and Google Scholar databases. It was based on the Population, Intervention, Comparison, Outcomes, and Study Design (PICOS) framework. Also, the search was not restricted to any particular year of publication, and studies could be published in English or Spanish. Study screening and selection, risk of bias assessment, and data extraction were performed by peer reviewers. A total of 21 articles published between 2011 and 2022 met the inclusion criteria: twenty were observational studies, and one was a randomized clinical trial. Regarding the risk of bias, five studies had a serious risk, fifteen had a moderate risk, and one had an undetermined risk. Concerning the type of intervention, seven studies compared telemedicine with standard care. When examining effectiveness by gestational week subgroups using risk difference (RD), the meta-analysis revealed a slight advantage of telemedicine over in-person care: for pregnancies up to the ninth week (RD = 0.01; 95 % CI – 0.00, 0.03); for pregnancies up to the tenth week (RD = 0.01; 95 % CI – 0.00, 0.01); and for pregnancies up to the twelfth week (RD = 0.01; 95 % CI – 0.01, 0.02). With respect to the other meta-analyses, no differences were observed in the occurrence of adverse events or satisfaction with the service when comparing the two forms of healthcare delivery.

Added value of this study: No studies have been conducted on telemedicine medication abortion in Colombia, and scientific evidence on the subject is scarce for Latin America.

Implications of all the available evidence: By characterizing users of telemedicine medication abortion services, it is possible to gather valuable information to improve and modify healthcare services, thus satisfactorily responding to women's sexual and reproductive health needs.

1 Introduction

Universal access to sexual and reproductive health services is essential, as stated in the Universal Declaration of Human Rights and other international and regional conventions founded on the principles of equality and non-discrimination [1]. In certain regions, these principles are still in the early stages of implementation. In nations with unfavorable conditions, pregnant women seeking these services must resort to clandestine institutions, increasing the risk of complications and death [2]. The World Health Organization (WHO) has urged member countries to develop policies for the decriminalization of abortion and issued recommendations for healthcare systems to prioritize safe abortion services [1,[3], [4], [5], [6]].

Unsafe abortion is the termination of a pregnancy by individuals lacking sufficient technical knowledge or under conditions that do not meet the minimal medical standards [7]. It is a determinant of maternal morbidity and mortality, claiming the lives of around 47,000 pregnant women worldwide each year [1,6]. Approximately 60 % of unsafe abortions occur in Africa, and 30 % in Latin America [8]. This lack of access to safe, timely, and affordable abortion services increases the risk of health complications for pregnant women and imposes costs on healthcare services, making it a human rights and public health concern [9].

Currently, more countries are decriminalizing abortion. In Colombia, public health policies and laws have been modified to comply with international guidelines. Abortion in Colombia is legal and covered by the health system in cases of rape, risk to the mother's health, and if extrauterine life is not possible. As of 2022, it's legal until the 24th week of gestation for any reason [10,11].

MAB up to the twelfth week of pregnancy has been a significant milestone due to the simplicity and safety of the procedure. This treatment is available in healthcare institutions, or it can be self-managed at home [1]. The outpatient option frees users from the structural limitations of healthcare services [12] and opens possibilities for innovative care alternatives, such as the use of telemedicine services [13,12].

Telemedicine was crucial during the COVID-19 pandemic, helping healthcare systems adapt to mobility restrictions and lockdown measures. It reduced geographical barriers, improved care quality and timeliness, optimized costs, and reduced waiting times [[14], [15], [16], [17], [18], [19], [20]]. In sexual and reproductive health, telemedicine can be used for preventive care, contraceptive counselling, family planning, infertility studies, MAB, etc. [18].

Colombia's healthcare system is regulated by Law 100 of 1993. Higher income earners contribute a larger proportion to healthcare to support those with limited resources. For this reason, there are two affiliation regimes: contributory (workers and their families) and subsidized (unemployed people). There is also a third special scheme, which protects officials of government institutions, the armed forces and ministries, among others [21]. In all the regimes, health services are provided through outsourcing, for example: Profamilia.

Several health administrators have partnered with Profamilia, a Colombian non-governmental organization, and its core mission is to advocate for the respect and exercise of Colombians’ sexual and reproductive rights. In 2021, powered by scientific findings and technological changes, Profamilia launched the Mi cuerpo, Mi autonomía-MIA (My Body, My Autonomy) program. It provides professional guidance to pregnant women seeking voluntary termination of pregnancy up to the twelfth week through self-managed MAB. Telemedicine approach is adopted for this service model, which has demonstrated effectiveness and safety on par with or better than in-person care [[22], [23], [24], [25]].

This study aims to characterize the users of the MIA program and to evaluate the safety and effectiveness of MAB through telemedicine in Colombia, a country with high wealth inequality and limited healthcare access for rural residents, ethnic groups, migrants, and those in the subsidized healthcare system [26].

2 Methods

2.1 Study design and participants

We conducted a retrospective cohort study including all pregnant women who requested telemedicine abortion services within the first trimester of pregnancy through the Profamilia MIA program in Colombia, from August 1st, 2021, to August 31st, 2022.

The MIA program provides services throughout Colombia. It can be paid for by health insurers or by the client. Pregnant women may contact MIA staff at any time of the day, seven days a week, via the website, telephone, or in-person [11]. Physicians assesses user's gestational weeks based on their Last Menstrual Period (LMP) to determine their eligibility for MAB. If the LMP is not reliable, an ultrasound or a blood test is advised to estimate gestational length.

During the telemedicine consultation, physician prescribes the MIA kit, which includes one tablet of mifepristone 200 mg for oral administration and four tablets of misoprostol 200 mg for sublingual administration 36 h after, in accordance with the WHO's guidelines for MAB [27]. Additionally, the kit contains a urine pregnancy test, tablets of ibuprofen 400 mg, a condom, and oral contraceptives for 21 or 28 days. Users are informed about potential side effects, warning signs, and necessary visits to the emergency department, as well as contraceptive methods.

2.2 Data sources

During the initial consultation with the physician, sociodemographic data, clinical and obstetrical history, and clinical information regarding the user's gestational status were recorded.

The follow-up calls to establish treatment success or failure and secondary adverse events was made 21 days after the start of treatment. A satisfaction survey was also sent via e-mail which could be answered on a voluntary basis.

The effectiveness of MAB was obtained by a rapid urine pregnancy test performed 15 days after initiation of treatment. A negative result was interpreted as a successful abortion and the user was referred to a family planning clinic. Otherwise, the individual was advised to go to Profamilia for an in-person consultation to decide whether to continue with the pregnancy or to resort to an extra dose of misoprostol or manual vacuum aspiration.

2.3 Data collection

Data were obtained from Profamilia's Health Information Systems database. Each record underwent data quality control, and the completeness of the variables was also validated.

2.4 Variables

The sociodemographic variables included age, area of residence, city, socioeconomic status, level of education, healthcare affiliation regime, marital status, and ethnic minority group. The clinical variables included gestational weeks at the time of the first consultation, and number of previous pregnancies.

The age variable was presented as continuous and divided into four groups: <18, 18–24, 25–34, and ≥35. The six socioeconomic strata were condensed into three groups: low [1,2], middle [3,4], and high [5,6]. Ethnicity was classified into two categories: none and others (indigenous, Afro-descendant, Raizal, Palenque, and Rom). Regarding marital status, participants who identified themselves as separated, divorced, or widowed were grouped with those in the “single” category, while those in de facto unions were grouped with those in the “married” category. Gestational weeks were divided into two categories: less than or equal to eight weeks and more than eight weeks. This was done because kit delivery and medication intake could take up to three weeks, which could exceed the twelve-week threshold recommended for MAB. The location of the users was classified as urban or rural in accordance with the classification of the National Administrative Department of Surveys (DANE) [28].

2.5 Results definition

All data collected were self-reported by users, except for gestational weeks, which were estimated through blood tests or ultrasound for some observations.

Successful abortion was defined according to the Medical Abortion Reporting of Efficacy (MARE) guidelines, which define it as the “successful expulsion of the intrauterine pregnancy without need for surgical intervention” [29].

Safety results were categorized into three groups: potentially dangerous signs (excessive bleeding, pain not relieved by analgesics, fever greater than 38 °C, and signs suggestive of local infection of the reproductive system), potentially adverse events (requirement of intravenous fluids, blood transfusion and hospitalization) [30] and complications (infection, hemorrhage, uterine rupture or death) [31]. Additionally, symptoms such as pain, bleeding, nausea/vomiting, diarrhea, chills, and headache are described as common side effects.

Using a Net Promoter Score (NPS) of 0–10, users were evaluated on their satisfaction. An overall rating of 10 indicates absolute satisfaction, while a rating of 0 indicates the opposite. The users are classified according to their scores, with those who receive a score of 9 or 10 points being classified as service promoters and those who receive a score of 8 or less being classified as non-service promoters [32].

2.6 Statistical methods

The study compared sociodemographic and clinical variables among participants receiving MAB services, those without, and those providing follow-up information. Among participants with follow-up data, comparisons were made based on the MAB results. Since not all observations include satisfaction information, The sociodemographic characteristics of users who completed the satisfaction survey are compared to those who didn't. This was done to identify potential biases in the satisfaction results.

We conducted a geographical analysis to identify the main areas of residence of telemedicine service users. Based on this information, the departments with the highest number of users in the territory were identified. The free software EpiInfo V.7.2 was used for this purpose.

For qualitative variables, absolute frequencies and percentages were used and compared using the Chi-square test or Fisher's exact test. Quantitative variables were described using the median and interquartile range and compared using the Mann–Whitney U test due to their non-normal distribution. A significance level (α) of 0.05 was considered, and data were analyzed using the statistical software R (version 4.2.1).

3 Results

3082 pregnant women requested telemedicine MAB services through the Profamilia MIA program between August 1st, 2021, and August 31st, 2022. Of these, nine (0.3 %) were not eligible for the procedure. Fig. 1 describes the reasons why the nine pregnant women were not eligible, the process of classifying clients throughout the study analysis, and the individuals who were not followed up effectively.Fig. 1 Flowchart of Profamilia's telemedicine medication abortion service, Colombia, 2021–2022.

Fig. 1

3.1 Care process

Eighty-seven per cent of users were aged between 18 and 35. The majority lived in urban areas (98 %), had a high school education (82 %), were covered by compulsory health insurance (72 %), were single (91 %) and had no ethnic affiliation (90 %). 88.3 % of clients started treatment before the 8th week of pregnancy and 49.9 % had a previous pregnancy (Table 1).Table 1 Sociodemographic characteristics of Profamilia's telemedicine medication abortion service users, by follow-up status and medication abortion results, Colombia, 2021–2022.

Table 1Characteristics	Users who received the service	Abortion result	
Total	With follow-up	Without follow-up	p-value	Total	Medication abortion	Procedural abortion	p-value	
n = 3073	n = 1443	n = 1630	n = 1247	n = 1184	n = 63	
n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	
Sociodemographic rowhead	
 Age	
 Min-Max	13–47	15–46	13–47	–	15–46	15–46	18–43	–	
 Median/[IQR]	25/[22–29]	25/[22–30]	25/[21–29]	0.036a	25/[22–30]	25/[22–29]	28/[24–32]	0.002a	
 <18 years	108 (3.5)	42 (2.9)	66 (4.0)	0.107b	38 (3.0)	38 (3.2)	0 (0.0)	0.020b	
 18–24 years	1326 (43.2)	605 (41.9)	721 (44.2)	529 (42.4)	510 (43.1)	19 (30.2)	
 25–34 years	1359 (44.2)	654 (45.3)	705 (43.3)	564 (45.2)	531 (44.8)	33 (52.4)	
 ≥35 years	280 (9.1)	142 (9.8)	138 (8.5)	116 (9.3)	105 (8.9)	11 (17.5)	
 Area of residence	
 Urban	3004 (97.8)	1414 (98.0)	1590 (97.5)	0.780b	1223 (98.1)	1162 (98.1)	61 (96.8)	0.344c	
 Rural	64 (2.1)	29 (2.0)	35 (2.1)	24 (1.9)	22 (1.9)	2 (3.2)	
 Missing	5 (0.2)	0 (0.0)	5 (0.3)	–	0 (0.0)	0 (0.0)	0 (0.0)	–	
 Socioeconomic status	
 Low (strata 1 and 2)	2605 (84.8)	1203 (83.4)	1402 (86.0)	0.026b	1042 (83.6)	989 (83.5)	53 (84.1)	0.508b	
 Middle (strata 3 and 4)	449 (14.6)	230 (15.9)	219 (13.4)	198 (15.9)	189 (16.0)	9 (14.3)	
 High (strata 5 and 6)	14 (0.5)	10 (0.7)	4 (0.2)	7 (0.6)	6 (0.5)	1 (1.6)	
 Missing	5 (0.2)	0 (0.0)	5 (0.3)	–	0 (0.0)	0 (0.0)	0 (0.0)	–	
 Level of education	
 Up to primary school	31 (1.0)	13 (0.9)	18 (1.1)	0.006b	10 (0.8)	9 (0.8)	1 (1.6)	0.465b	
 Up to secondary school	2507 (81.6)	1133 (78.5)	1374 (84.3)	995 (79.8)	949 (80.2)	46 (73.0)	
 Two- or three-year associate degree	157 (5.1)	69 (4.8)	88 (5.4)	57 (4.6)	52 (4.4)	5 (7.9)	
 Undergraduate/Postgraduate degree	151 (4.9)	90 (6.2)	61 (3.7)	79 (6.3)	75 (6.3)	4 (6.3)	
 Missing	227 (7.4)	138 (9.6)	89 (5.5)	–	106 (8.5)	99 (8.4)	7 (11.1)	–	
 Healthcare affiliation regimen	
 Subsidized	472 (15.4)	219 (15.2)	253 (15.5)	<0.001b	196 (15.7)	182 (15.4)	14 (22.2)	0.346b	
 Contributory	2220 (72.2)	988 (68.5)	1232 (75.6)	856 (68.6)	816 (68.5)	40 (63.5)	
 Special regime	375 (12.2)	236 (16.4)	139 (8.5)	195 (15.6)	186 (15.7)	9 (14.3)	
 Missing	6 (0.2)	0 (0.0)	6 (0.4)	–	0 (0.0)	0 (0.0)	0 (0.0)	–	
 Marital status	
 Single/Separated/Divorced/Widowed	2790 (90.8)	1302 (90.2)	1488 (91.3)	0.197b	1302 (90.2)	1049 (91.5)	253 (85.5)	0.079b	
 Married/De facto union	278 (9.0)	141 (9.8)	137 (8.4)	141 (9.8)	98 (8.5)	43 (14.5)	
 Missing	5 (0.2)	0 (0.0)	5 (0.3)	–	0 (0.0)	0 (0.0)	0 (0.0)	–	
 Ethnicity	
 None	3043 (99.0)	1433 (99.3)	1610 (98.8)	0.596b	1239 (99.4)	1176 (99.3)	63 (100.0)	0.660c	
 Other (Afro-descendant, Raizal)	24 (0.8)	10 (0.7)	14 (0.9)	8 (0.6)	8 (0.7)	0 (0.0)	
 Missing	6 (0.4)	0 (0.0)	6 (0.4)	–	0 (0.0)	0 (0.0)	0 (0.0)	–	
Clinical	
 Weeks' gestation	
 Min-Max	2.5–12.4	2.6–10.0	2.5–12.4	–	2.6–10.0	2.6–10.0	3.0–8.5	–	
 Median [IQR]	6.4 [5.6–7.3]	6.3 [5.5–7.2]	6.4 [5.6–7.3]	0.006a	6.3 [5.5–7.2]	6.3 [5.5–7.2]	6.3 [5.4–7.1]	0.530a	
 ≤8 weeks	2714 (88.3)	1305 (90.4)	1409 (86.6)	<0.001b	1128 (90.5)	1068 (90.2)	60 (95.2)	0.185b	
 >8 weeks	356 (9.6)	138 (9.6)	218 (13.4)	119 (9.5)	116 (9.8)	3 (4.8)	
 Previous pregnancies	
 Yes	1533 (49.9)	696 (48.2)	837 (51.3)	0.116b	586 (47.0)	552 (46.6)	34 (54.0)	0.296b	
 No	1511 (49.2)	729 (50.5)	782 (48.0)	646 (51.8)	617 (51.2)	29 (46.0)	
 Missing	29 (0.9)	18 (1.2)	11 (0.7)	–	15 (1.2)	15 (1.3)	0 (0.0)	–	
a Mann–Whitney U test.

b Chi-Square Test of Independence.

c Fisher's Exact test.

Out of the total participants who received MAB services, 1443 (46.9 %) provided follow-up information. Table 1 shows the characteristics of users with and without follow-up data.

Users without follow-up data had gestation exceeding eight weeks, lower socioeconomic status and be affiliated with subsidized healthcare. Those who provide follow-up info are more likely to have higher education.

Less than 1 % of the users served by the MIA program belonged to one of the ethnic groups identified in Colombian territory, and 2.1 % of the users resided in rural areas. Fig. 2 shows the geographical location of users. Fig. 2A shows the places of residence distributed throughout the Colombian territory. Fig. 2b shows that the five departments with the highest number of users were Antioquia (24.0 %), Bogotá D.C. (18.9 %), Valle del Cauca (8.9 %), Atlántico (8.5 %) and Norte de Santander (6.0 %), which together account for 66 % of all users.Fig. 2 Figure 2A. Geographical distribution of MIA program 2021–2022 service users, Colombia. Figure 2B.The five departments with the highest number of users of MIA program, Colombia.

Fig. 2

3.2 Abortion result

Out of 1443 users followed, 1247 (86.4 %) had a confirmed complete abortion outcome through a pregnancy test or ultrasound. The remaining 196 (13.6 %) users needed an ultrasound to confirm the success of the abortion but didn't have a second follow-up.

Of the 1247 individuals who had an abortion and confirmed results, 1184 (94.9 %) had a successful MAB. The remaining 63 users (5.1 %) required procedural abortion. Table 1 displays user characteristics for those who completed abortion. The group of users who needed surgical intervention had a higher average age than those who completed the process with medication (28 vs. 25 years old; p = 0.002). No differences were observed in other sociodemographic characteristics.

3.3 Safety results

Table 2 showcases MAB procedure's safety results. Regarding common side effects, pain was the most common (89.1 %). Of the 1247 users who were followed up, 13.2 % reported fever, which was the most frequent potential sign of risk. Twenty-one (1.7 %) sought emergency department consultation, 20 of whom were in the complete abortion group. Three (0.2 %) other users required hospitalization and two (0.2 %) required intravenous antibiotics, all in the complete abortion group. In the complications results, four cases of infection (0.3 %) were reported, all of which were in the complete abortion group. No blood transfusions or deaths were reported.Table 2 Effectiveness and safety outcomes of medical abortion in MIA users, Profamilia, Colombia, 2021–2022.

Table 2Results	Medication abortion results	
Total	Complete abortion	Incomplete abortion	p-value	
n = 1247	n = 1184	n = 63	
n (%)	n (%)	n (%)	
Common side effects	
 Bleeding	
 Yes	663 (53.2)	628 (53.0)	35 (55.6)	0.697a	
 No	584 (46.8)	556 (47.0)	28 (44.4)		
 Pain	
 Yes	1111 (89.1)	1057 (89.3)	54 (85.7)	0.377a	
 No	136 (10.9)	127 (10.7)	9 (14.3)		
 Nausea and vomiting	
 Yes	421 (33.8)	404 (34.1)	17 (27.0)	0.243a	
 No	826 (66.2)	780 (65.9)	46 (73.0)		
 Diarrhea	
 Yes	325 (26.1)	308 (26.0)	17 (27.0)	0.864a	
 No	922 (73.9)	876 (74.0)	46 (73.0)		
 Chills	
 Yes	449 (36.0)	422 (35.6)	27 (42.9)	0.245a	
 No	798 (64.0)	762 (64.4)	36 (57.1)		
 Headache	
 Yes	88 (7.1)	85 (7.2)	3 (4.8)	0.617b	
 No	1159 (92.9)	1099 (92.8)	60 (95.2)		
Potential warning wigns	
 Fever	
 Yes	165 (13.2)	157 (13.3)	8 (12.7)	0.898a	
 No	1082 (86.8)	1027 (86.7)	55 (87.3)		
Potential adverse events	
 Emergency care	
 Yes	21 (1.7)	20 (1.7)	1 (1.6)	0.951b	
 No	1226 (98.3)	1164 (98.3)	62 (98.4)		
 Hospitalization	
 Yes	3 (0.2)	3 (0.3)	0 (0.0)	0.689b	
 No	1244 (99.8)	1181 (99.7)	63 (100.0)		
 Transfusion	
 Yes	0 (0.0)	0 (0.0)	0 (0.0)	–	
 No	1247 (100.0)	1184 (100.0)	63 (100.0)		
 Requirement of intravenous antibiotics	
 Yes	2 (0.2)	2 (0.2)	0 (0.0)	0.744b	
 No	1245 (99.8)	1182 (99.8)	63 (100.0)		
Complications	
 Infections	
 Yes	4 (0.3)	4 (0.3)	0 (0.0)	0.813b	
 No	1243 (99.7)	1180 (99.7)	63 (100.0)		
 Death, uterine rupture and hemorrhage	
 Yes	0 (0.0)	0 (0.0)	0 (0.0)	–	
 No	1247 (100.0)	1184 (100.0)	63 (100.0)		
 Time to start treatment	
 Min-Max	0.0–38.0	0.0–38.0	0.0–22.0	–	
 Median/[IQR]	5.0/[3.0–7.0]	5.0/[3.0–7.0]	5.0/[3.0–7.0]	0.539c	
 1–7 days	974 (78.1)	922 (77.9)	52 (82.5)	0.677a	
 8–15 days	245 (19.7)	235 (19.9)	10 (15.9)		
 >15 days	28 (2.2)	27 (2.3)	1 (1.6)		
a Chi Square Test of Independence.

b Fisher's exact test.

c Mann Whitney U test.

The time between consultation and the start of medication intake ranged from zero to 38 days, with a median of five days. 76.8 % of users received the abortion kit within the first seven days following consultation.

3.4 Satisfaction results

Satisfaction survey was answered by 194 of 3073 (5.3 %). Of these, 168 (86.6 %) were classified as promoters of the service and 26 (13.4 %) users who do not recommend the service. Seventy (36.1 %) users who responded to the survey were not effectively followed-up. Sensitivity analysis showed that there is no difference in the proportions of MAB success and having responded to the satisfaction survey or not (62.4 % vs 39.9 %; p = 0.158). Users who do not identify with any ethnicity and who have one or more previous pregnancies are more likely to participate in the satisfaction survey than those who do not respond, 99 % vs. 33.3 % (p = 0.001) and 50.4 % vs. 41.8 % (p = 0.015), (see Supplementary Table S1).

4 Discussion

This study aimed to describe the results of the first-trimester MAB service delivered via telemedicine at the non-governmental organization Profamilia.

One hundred eight (3.5 %) users were under 18 years old. The same age group, in European population studies, is approximately 0.4 % [33], while in American studies, it may range from 1 % to 10 % [34,35]. Profamilia's abortion telemedicine service has no age limit, although it is possible that certain pre-existing conditions could exclude certain people from accessing these services. A possibility may be lacking information and economic resources, or that pregnant women under 18 are subject to terms in health plans that violate their wishes for confidentiality and autonomy.

One concern is the low proportion of users who are residents of rural areas (2 %). One objective of remote healthcare services is to facilitate access to healthcare for people in remote regions. Geographical analysis shows that most service requests come from the central, northwest, and northeast regions. From the eastern and south-eastern regions of the country, as well as from the Pacific coast, users were scarce. This distribution may be related to the fact that these regions have higher poverty rates, fewer and lower quality educational institutions and, difficult access to computer and telecommunication technologies [36,37]. It is also observed that the five departments with the highest number of users are the five departments with the highest economic production in the country [38].

97.8 % of users began treatment within 15 days or less. This is favorable because the MIA program only accepts users within 12 weeks of pregnancy, ensuring that the abortion procedure will take place during the eligible weeks. Nonetheless, 2.2 % started treatment after 15 days. Delays in initiating treatment may necessitate the administration of additional doses of misoprostol or the performance of medical procedures [39].

We found that 94 % of the MAB was successful, a rate similar to those reported in studies that have examined telemedicine either separately or compared it with in-person care in countries such as the United States, Australia, or Mexico [16,19,23,25,34,[40], [41], [42], [43]].

Concerning MAB-related complications, some studies report incidence rates below 0.003 % [19,[23], [24], [25]], while others report values like those found in this study, close to 0.3 % [25,33,35,43]. It is essential to acknowledge that a few of the articles under consideration may diverge in their conceptualization of complications. Indeed, they include within the same category of events, whereas in this study, have been classified as potentially adverse.

Only 5 % of users voluntarily responded to the satisfaction survey and, the sensitivity analysis found statistically significant differences when comparing ethnicity and previous pregnancies. Thus, these results may not be representative of the population and may be affected by issues of internet access, privacy, or cultural or religious reasons, among others.

The follow-up rate was lower than that reported in other studies [22,23,40,43,44]. However, this is not an issue of concern since, according to WHO guidelines [1], the low rate of complications related to the use of mifepristone and/or misoprostol means that loss to follow-up cannot be an obstacle to accessing abortion services.

Limitations include inadequate characterization of self-reported secondary events and lack of integration of medical care information for emergency services or hospitalization. Additionally, users did not provide medical records or epicrises of their care for reported events. Finally, the satisfaction results may not accurately represent the entire user population because the sensitivity analysis indicates that the response rate to the survey may rise in the event of a successful medication procedure and side effects abscence.

MAB care delivered via telemedicine in developing countries can achieve standards of quality and safety comparable to those observed in developed countries. Consequently, the information presented is intended to promote confidence and enable rural or remote users to make informed decisions without having to rely on specialized health infrastructure. Further, it aims to inform political institutions, health service providers, and healthcare staff about the importance of implementing and strengthening information and access strategies.

Ethical approval

The study received approval from the Profamilia Research Ethics Committee under Approval Record No. 5 of 2023. Additionally, participants provided written informed consent to participate in teleconsultation and receive MAB services, and they also consented to the use of their data for research purposes.

Funding source

This research was supported by Profamilia (Colombia) and Ipas Latin America and the Caribbean. Ipas researchers have worked in the conceptualization and manuscript development.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A Supplementary data

The following is the supplementary data to this article:Multimedia component 1

Multimedia component 1

Acknowledgments

We thank IPAS Latin America and the Caribbean and Profamilia, especially to Lucy Alexandra Betancourt (Health Information System Coordinator), and Giovanni Guerrero Conde (Clinical Quality Management Director), for their cooperation in data collection.

Appendix A Supplementary data to this article can be found online at https://doi.org/10.1016/j.puhip.2024.100539.
==== Refs
References

1 World Health Organization Abortion care guideline: executive summary Available from http://apps.who.int/bookorders 2022
2 United Nations. Department of Economic and Social Affairs. Population Division Abortion policies and reproductive health around the world [Internet] [cited 2023 Feb 13]. 48 p. Available from: https://www.un.org/en/development/desa/population/publications/pdf/policy/AbortionPoliciesReproductiveHealth.pdf 2014
3 World Health Organization Medical management of abortion [Internet] http://apps.who.int/bookorders 2019
4 World Health Organization Consolidated Telemedicine Implementation Guide 2022
5 World Health Organization Health worker roles in providing safe abortion care and post-abortion contraception [cited 2023 Feb 12]; Available from: https://apps.who.int/iris/handle/10665/204374 2015
6 World Health Organization Safe abortion: technical and policy guidance for health systems [Internet]. 2° Edición https://apps.who.int/iris/handle/10665/77079 2012
7 World Health Organization The Prevention and Management of Unsafe Abortion: Report of a Technical Working Group 1992 World Health Organization
8 Singh S. Remez L. Sedgh G. Kwok L. Onda T. Abortion worldwide 2017: uneven progress and unequal access [internet] https://www.guttmacher.org/report/abortion-worldwide-2017 2018
9 Zane S. Creanga A.A. Berg C.J. Pazol K. Suchdev D.B. Jamieson D.J. Abortion-related mortality in the United States: 1998-2010 Obstet. Gynecol. 126 2 2015 Aug 23 258 265 26241413
10 Corte Constitucional de la República de Colombia Sentencia C-355 de 2006 May 10, 2006 Colombia
11 Corte Constitucional de la República de Colombia Sentencia C-055 de 2022. C-055–22 Colombia https://www.corteconstitucional.gov.co/Relatoria/2022/C-055-22.htm#:~:text=La20mujer20que20causare20su,prevista20en20el20inciso20anteriorE2809D Feb 21, 2022
12 Profamilia. Asociación Profamilia y MEXFAM Acceso al aborto seguro en tiempos de COVID-19: desafíos y oportunidades para la prestación del servicio de aborto por telemedicina en Colombia y México 2021 Bogotá D.C y Ciudad de México [Internet] https://profamilia.org.co/wp-content/uploads/2021/05/Acceso-al-aborto-seguro-en-tiempos-de-COVID-19-Digital.pdf
13 WHO Global Observatory for eHealth Telemedicine: Opportunities and Developments in Member States: Report on the Second Global Survey on eHealth 2010 World Health Organization [Internet]. 2009 https://apps.who.int/iris/handle/10665/44497
14 Organisation for Economic Co-operation and Development The future of telemedicine after COVID-19 [Internet] https://read.oecd-ilibrary.org/view/?ref=1178_1178746-yy7ysc5k0j&title=The-future-of-telemedicine-after-COVID-19 2023 Jan
15 Centers for Disease Control and Prevention Telemedicina, ¿qué significa y por qué le debería importar? [Internet] https://www.cdc.gov/coronavirus/2019-ncov/global-covid-19/telemedicine-sp.html 2020
16 Nortén H. Ilozumba O. Wilkinson J. Gemzell-Danielsson K. Gomperts R. 10-year evaluation of the use of medical abortion through telemedicine: a retrospective cohort study BJOG 129 1 2022 Jan 1 151 159 34018294
17 Profamilia. Asociación Profamilia y MEXFAM Acceso al aborto seguro en tiempos de COVID-19: desafíos y oportunidades para la prestación del servicio de aborto por telemedicina en Colombia y México 2021 Bogotá D.C y Ciudad de México [Internet] https://profamilia.org.co/wp-content/uploads/2021/05/Acceso-al-aborto-seguro-en-tiempos-de-COVID-19-Digital.pdf
18 Lee S. Hitt W.C. Clinical applications of telemedicine in gynecology and women's health Obstet. Gynecol. Clin. N. Am. 47 2020 259 270 W.B. Saunders
19 Aiken A. Lohr P. Lord J. Ghosh N. Starling J. Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study BJOG 128 9 2021 Aug 1 1475 1476 33982401
20 Grossman D. Telemedicine for medical abortion – time to move towards broad implementation BJOG: an International Journal of Obstetrics and Gynaecology 126 2019 Blackwell Publishing Ltd 1103 31009164
21 Ministerio de Salud y Protección Social Aseguramiento al Sistema General de Seguridad Social en Salud [Internet] 2014 Bogotá https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VP/DOA/RL/cartillas-de-aseguramiento-al-sistema-general-de-seguridad-social-en-salud.pdf
22 Wiebe E.R. Campbell M. Ramasamy H. Kelly M. Comparing telemedicine to in-clinic medication abortions induced with mifepristone and misoprostol Contraception 2 2020 Jan 1 100023
23 Kohn J.E. Snow J.L. Simons H.R. Seymour J.W. Thompson T.A. Grossman D. Medication abortion provided through telemedicine in four U.S. States Obstet. Gynecol. 134 2 2019 Aug 1 343 350 31306317
24 Grossman D. Grindlay K. Safety of medical abortion provided through telemedicine compared with in person Obstetrics and Gynecology 2017 Lippincott Williams and Wilkins 778 782
25 Endler M. Petro G. Danielsson K.G. Grossman D. Gomperts R. Weinryb M. A telemedicine model for abortion in South Africa: a randomised, controlled, non-inferiority trial Lancet 400 10353 2022 Aug 27 670 679 10.1016/S0140-6736(22)01474-X 36030811
26 Banco Mundial. Colombia: panorama general [Internet] https://www.bancomundial.org/es/country/colombia/overview 2023
27 World Health Organization Medical Management of Abortion 1–54 2018
28 Departamento Administrativo Nacional de Estadística - DANE División político administrativa [Internet] https://www.dane.gov.co/index.php/estadisticas-por-tema?view=article&id=488:division-polistico-administrativa&catid=72 2024
29 Creinin M.D. Chen M.J. Medical abortion reporting of efficacy: the MARE guidelines Contraception 94 2016 Elsevier USA 97 103 27129936
30 Jayaweera R. Egwuatu I. Nmezi S. Kristianingrum I.A. Zurbriggen R. Grosso B. Medication abortion safety and effectiveness with misoprostol alone JAMA Netw. Open 6 10 2023 Oct 27 e2340042
31 Gerdts C. Bell S.O. Shankar M. Jayaweera R.T. Owolabi O. Beyond safety: the 2022 WHO abortion guidelines and the future of abortion safety measurement BMJ Glob. Health 7 6 2022 Jun 20 e009557
32 Koladycz R. Fernandez G. Gray K. Marriott H. The Net promoter score (NPS) for insight into client experiences in sexual and reproductive health clinics Glob. Health Sci. Pract. 6 3 2018 Oct 3 413 424 30072372
33 Aiken A.R.A. DIgol I. Trussell J. Gomperts R. Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland BMJ 357 2017
34 Peña M. Figueroa Flores K. Muñoz Ponce M. Facio Serafín D. Camarillo Zavala A.M. Ruiz Cruz C. Telemedicine for medical abortion service provision in Mexico: a safety, feasibility, and acceptability study Contraception 114 2022 Oct 1 67 73 35753406
35 Aiken A.R.A. Romanova E.P. Morber J.R. Gomperts R. Safety and effectiveness of self-managed medication abortion provided using online telemedicine in the United States: a population based study The Lancet Regional Health - Americas [Internet] 10 2022 100200 10.1016/j
36 Departamente Administrativo Nacional de Estadística - DANE Cuentas departamentales Producto Interno Bruto por Departamento 2022 provisional 2024 Mar [Internet]. Bogotá D.C. https://www.dane.gov.co/files/operaciones/PIB/bol-PIBDep-2022p.pdf
37 Departamento Administrativo Nacional de Estadística - DANE Tecnologías de la información y las comunicaciones (TIC) [cited 2024 Mar 31]. Encuesta de Tecnologías de la Información y las Comunicaciones en Hogares (ENTIC Hogares). Available from: https://www.dane.gov.co/index.php/estadisticas-por-tema/tecnologia-e-innovacion/tecnologias-de-la-informacion-y-las-comunicaciones-tic/encuesta-de-tecnologias-de-la-informacion-y-las-comunicaciones-en-hogares-entic-hogares 2022
38 Departamento Administrativo Nacional de Encuestas. Cuentas Departamentales Producto Interno Bruto por Departamento 2022 [Internet].Bogotá D.C https://www.dane.gov.co/files/operaciones/PIB/bol-PIBDep-2022p.pdf 2024 Mar
39 World Health Organization Abortion Care Guideline 2022 Who Ginebra 186 Internet https://www.who.int/es/publications/i/item/9789240039483
40 Hyland P. Raymond E.G. Chong E. A direct-to-patient telemedicine abortion service in Australia: retrospective analysis of the first 18 months Aust. N. Z. J. Obstet. Gynaecol. 58 3 2018 Jun 1 335 340 29603139
41 Reynolds-Wright J.J. Johnstone A. McCabe K. Evans E. Cameron S. Telemedicine medical abortion at home under 12 weeks' gestation: a prospective observational cohort study during the COVID-19 pandemic BMJ Sex Reprod Health 47 4 2021 Oct 1 246 251
42 Seymour J.W. Melville C. Thompson T.A. Grossman D. Effectiveness and safety of a direct-to-patient telehealth service providing medication abortion targeted at rural and remote populations: cross-sectional findings from Marie Stopes Australia Contraception 115 2022 Nov 1 67 68 35753405
43 Chong E. Shochet T. Raymond E. Platais I. Anger H.A. Raidoo S. Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic Contraception 104 1 2021 Jul 1 43 48 33781762
44 Mezela I. Van Pachterbeke C. Jani J.C. Badr D.A. Effectiveness and acceptability of “at home” versus “at hospital” early medical abortion – a lesson from the COVID-19 pandemic: a retrospective cohort study Eur. J. Obstet. Gynecol. Reprod. Biol. 267 2021 Dec 150 154 34773877
